TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29754661
Drug: State-of-the-art rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: State-of-the-art rate or rhythm control drug therapy
Study: 29755707
Drug: Oral colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral colistin for 14 days
Study: 29756206
Drug: Oral pimasertib
Normalized name: capivasertib Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pimasertib (once daily for 5 days on/2 days off or twice daily continuously) combined with weekly gemcitabine (1,000 mg/m2)
Study: 29756206
Drug: Oral pimasertib
Normalized name: capivasertib Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pimasertib
Study: 29756206
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine (1,000 mg/m2)
Study: 29756531
Drug: Pediatric Malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric Malaria Vaccine (GSK/PATH-MVI RTS,S)
Study: 29756750
Drug: Remifentanil IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil IV infusion of 0.005 µg/kg/min
Study: 29756750
Drug: Remifentanil IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil IV infusion of 0.05 µg/kg/min
Study: 29756750
Drug: Remifentanil IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil IV infusion of 0.1 µg/kg/min
Study: 29756750
Drug: Remifentanil IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil IV infusion of 0.15 µg/kg/min
Study: 29757399
Drug: DHEAS ≥40
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEAS ≥40 µg/dL
Study: 29759747
Drug: Average CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average CF categories of 0 to 10 g
Study: 29759747
Drug: Average CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average CF categories of 10 to 20 g
Study: 29759747
Drug: Average CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average CF categories of >20 g
Study: 29759747
Drug: CF of
Normalized name: Rovin-Cf OF Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF of 6.5 to 10.3 g
Study: 29760763
Drug: Vortioxetine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (5, 10, or 20 mg)
Study: 29761174
Drug: Elbasvir/grazoprevir (EBR/GZR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir (EBR/GZR) 50 mg/100 mg once daily for 12 weeks
Study: 29761903
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ABC294640 (sphingosine kinase 2 inhibitor) and ABT-199 (Bcl-2 inhibitor)
Study: 29761903
Drug: ABT-199 (Bcl-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-199 (Bcl-2 inhibitor)
Study: 29761903
Drug: ABC294640 (sphingosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC294640 (sphingosine kinase 2 inhibitor)
Study: 29762769
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for traumatic ASDH in younger patients
Study: 29762769
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for traumatic ASDH in elderly patients (≥70 yr)
Study: 29762769
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for traumatic ASDH in both younger and elderly patients
Study: 29765616
Drug: Cumulative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative steroid exposure (dose and duration) categorized into four levels: 0g (no exposure), >0 and <3.65g (<10mg/day for a year), ≥3.65g and <18.25g (1-5 years at 10mg/day), and ≥18.25g (>5 years at 10mg/day).
Study: 29766026
Drug: Intrathecal AAV9
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal AAV9 Gene Therapy
Study: 29766088
Drug: Community consultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community consultation (CC) process using random digit dialing technique
Study: 29766308
Drug: Laparoscopic TAPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic TAPP (l-TAPP)
Study: 29766322
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily microcirculatory monitoring
Study: 29766337
Drug: ASLAN-002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASLAN-002 at 300 mg BID
Study: 29766337
Drug: ASLAN-002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASLAN-002 at 450 mg BID
Study: 29766337
Drug: ASLAN-002 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASLAN-002 (all doses)
Study: 29766456
Drug: dNLR ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: dNLR ≥ 1.35 in hormone receptor-negative/HER2+ population
Study: 29766891
Drug: Intermittent heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent heparin infusion
Study: 29766891
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on warfarin
Study: 29767845
Drug: Defibrotide treatment
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide treatment after HSCT
Study: 29767845
Drug: Defibrotide treatment
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide treatment in paediatric patients
Study: 29767845
Drug: Defibrotide treatment
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide treatment in adult patients
Study: 29767845
Drug: Defibrotide treatment
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide treatment without multi-organ dysfunction (MOD)
Study: 29767845
Drug: Earlier initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Earlier initiation of defibrotide treatment after VOD/SOS diagnosis
Study: 29768372
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention program including wearable devices, App for recording activities, counseling, physical activity program, and pelvic floor treatment.
Study: 29769385
Drug: Panitumumab plus
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab plus Irinotecan (Pa 9 mg/m)
Study: 29770748
Drug: Raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir (RAL) therapy for 8 weeks
Study: 29773527
Drug: SMS triggered
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS triggered by missed or delayed doses
Study: 29773698
Drug: Baseline CoMiSS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline CoMiSS score before AAF treatment.
Study: 29774030
Drug: CSF-470 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSF-470 vaccine
Study: 29774030
Drug: Medium-dose IFNα2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose IFNα2b
Study: 29774169
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision.
Study: 29775078
Drug: Developmental Reciprocity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmental Reciprocity Treatment
Study: 29775807
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg on day 1 (21-day cycles)
Study: 29776373
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg intravenously, weekly pegylated recombinant arginase (BCT-100)
Study: 29777230
Drug: Baseline CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline CC levels
Study: 29777230
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in CC levels
Study: 29777402
Drug: Estrogen receptor/progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor/progesterone receptor-negative tumors
Study: 29777865
Drug: Switching therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching therapy
Study: 29778365
Drug: Cerebral microbleeds,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral microbleeds, diabetes, anticoagulant type, and HAS-BLED
Study: 29778515
Drug: Fractional intradermal
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional intradermal vaccination with quadrivalent conjugate vaccine (MenACWY-CRM)
Study: 29778515
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid conjugated vaccine (Nimenrix®)
Study: 29778738
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (methotrexate, vincristine, cisplatin, and cyclophosphamide) with high-risk patients receiving additional vinblastine.
Study: 29780414
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with trimethoprim-sulfamethoxazole
Study: 29780852
Drug: ADS-5102 (amantadine)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADS-5102 (amantadine) extended release capsules, 274 mg once daily at bedtime for up to two years
Study: 29781056
Drug: Lead-in cohort
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead-in cohort for carboplatin dose (arm 2a, n=6)
Study: 29782642
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg twice daily (q12h) until month 3, then adjusted to either 5 or 10 mg q12h.
Study: 29784469
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose (27,476 IU)
Study: 29784469
Drug: Tapered doses
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered doses (10,447 IU, 3013 IU, 587 IU)
Study: 29784469
Drug: Tapered doses
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered doses (158 IU, 31 IU)
Study: 29784747
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with immunotherapies for cutaneous melanoma
Study: 29784747
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment in metastatic melanoma
Study: 29785473
Drug: Plasma melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma melatonin levels correlation with postoperative morphine consumption
Study: 29785473
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in endogenous melatonin levels and morphine consumption
Study: 29785539
Drug: Spironolactone 200
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 200 mg single dose
Study: 29787575
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (IV tPA)
Study: 29787734
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) including specific diaphragm techniques
Study: 29788155
Drug: GDC-0575 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0575 and gemcitabine (1000 mg/m2 or 500 mg/m2)
Study: 29788155
Drug: GDC-0575 monotherapy
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0575 monotherapy
Study: 29788339
Drug: Cold chain
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold chain capacity of -60°C or colder for the STRIVE Ebola vaccine trial
Study: 29788340
Drug: Utilizing nurses
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utilizing nurses to staff the clinical trial for the Ebola vaccine.
Study: 29788349
Drug: Vaccine against
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine against Ebola
Study: 29788343
Drug: Immediate vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate vaccination with rVSV∆G-ZEBOV-GP vaccine (within 7 days)
Study: 29788345
Drug: rVSV∆G-ZEBOV-GP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV∆G-ZEBOV-GP Vaccine
Study: 29788348
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo or no vaccine)
Study: 29788497
Drug: GSK2256098 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256098 (1000 mg, 750 mg, 500 mg; dosed twice daily)
Study: 29788694
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months
Study: 29789238
Drug: LD-TDV administered
Normalized name: Tdvax
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-TDV administered by PharmaJet
Study: 29789238
Drug: Simultaneous injection
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous injection of two LD-TDV doses
Study: 29789238
Drug: LD-TDV (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-TDV (one or two doses)
Study: 29789238
Drug: LD-TDV (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-TDV (two doses given either concomitantly or 90 days apart)
Study: 29789971
Drug: Restriction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restriction of intravenous fluid element
Study: 29790103
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day)
Study: 29790125
Drug: Therapeutic interventions
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic interventions for the management of bleeding (fluid replacement, red blood cells transfusion, prothrombin complex concentrates, antifibrinolytic drugs, idarucizumab)
Study: 29792074
Drug: Tinnitus Retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus Retraining Therapy (TRT) including tinnitus-specific educational counseling and sound therapy
Study: 29792535
Drug: Veliparib (PARP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (PARP inhibitor) combined with topotecan
Study: 29793587
Drug: Cefazolin 4
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin 4 g dose administered before surgery
Study: 29794066
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day and octreotide 30 mg every 28 days
Study: 29794089
Drug: Interventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional treatment and Craniotomy
Study: 29794101
Drug: Systemic thrombolysis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic thrombolysis, endovascular treatment or both
Study: 29796622
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement intake >872 IU/d
Study: 29796622
Drug: 25(OH)D concentration
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentration <13 ng/mL
Study: 29796648
Drug: Essential Amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential Amino Acids (EAA) ingestion (6.8 g)
Study: 30846089
Drug: Paclitaxel drug-coated
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel drug-coated balloon treatment
Study: 29798831
Drug: Web-based transdiagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based transdiagnostic intervention (10 weeks, based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders)
Study: 29799100
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide (1.5 mg supratherapeutic dose)
Study: 29799545
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine 0.5 g/kg/day
Study: 29800309
Drug: Live zoster
Normalized name: Varicella zoster vaccine (live/attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live zoster VZVOka vaccine
Study: 29801465
Drug: Erlotinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib at 150 mg/day
Study: 29801483
Drug: Mass-treatment with
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass-treatment with praziquantel tablets as part of a Department of Health Mass-Treatment Campaign for schistosomiasis.
Study: 29801483
Drug: Focus Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focus Group Discussions and individual in-depth interviews to assess barriers to treatment.
Study: 29801520
Drug: G + A intervention
Normalized name: penicillin G Prefilled Syringe [Bicillin L-A]
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + A intervention (gambling intervention combined with problem drinking intervention)
Study: 29801520
Drug: G-only intervention
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-only intervention (targets only gambling issues)
Study: 29802091
Drug: Trauma-informed cognitive
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-informed cognitive behavioral therapy (CBT), eight-session antenatal intervention.
Study: 29802551
Drug: Amrubicin 40-80
Normalized name: valrubicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin 40-80 mg/m² intravenously combined with lenalidomide and weekly dexamethasone
Study: 29802636
Drug: Basal insulin-only
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin-only therapy
Study: 29803987
Drug: Coronary artery
Normalized name: Drug-coated coronary artery stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary artery function-guided diagnosis and treatment
Study: 29807287
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily for ≥5 days in combination with aspirin 100 mg
Study: 29807396
Drug: ASP8273 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8273 300 mg once daily
Study: 29807781
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor (CAR) T cells directed to prostate-specific membrane antigen (PSMA) co-expressing dominant-negative TGF-βRII (dnTGF-βRII)
Study: 29807781
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor (CAR) T cells directed to prostate-specific membrane antigen (PSMA) without dnTGF-βRII (implied control)
Study: 29807885
Drug: Gamified electronic
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamified electronic medication administration simulator
Study: 29808308
Drug: Afatinib (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (30, 40, or 50 mg) plus gemcitabine (1000 or 1250 mg/m2)
Study: 29808308
Drug: Afatinib (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (30, 40, or 50 mg) plus docetaxel
Study: 29812996
Drug: Dasatinib plus
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib plus intensive chemotherapy
Study: 29812996
Drug: Imatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib plus intensive chemotherapy (from COG AALL0031)
Study: 29843792
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg intravenously on days 1, 8, and 15 of cycle 1, and on day 1 of cycles 2-8 (24 weeks treatment period)
Study: 29843792
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg intravenously
Study: 29846848
Drug: Nab-paclitaxel maintenance
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy
Study: 29846848
Drug: Carboplatin +
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin + nab-paclitaxel combination therapy
Study: 29848478
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous traditional Chinese medicine (TCM)
Study: 29849651
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (SC-TCZ) 162 mg weekly
Study: 29849841
Drug: Analgesics for
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics for cancer-related pain
Study: 29849841
Drug: Physician assessment
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician assessment of analgesics
Study: 29851546
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg daily until progressive disease/unacceptable toxicity